ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4) WESTON, Fla., Jan. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for...

ZyVersa Therapeutics to Present at BIO CEO & Investor Conference CEO Stephen C. Glover to provide key updates on the development status of ZyVersa’s Phase 2a-ready cholesterol efflux mediator VAR 200 for renal disease and inflammasome ASC inhibitor, IC 100 WESTON,...

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event Live video webcast on Wednesday, January 18th at 2:00 PM ET Mr. Glover will highlight the development status of ZyVersa’s phase 2a-ready VAR 200 for renal disease and inflammasome ASC inhibitor, IC...